Rakuten Medical: COX-2 Inhibition Reduces Photoimmunotherapy-Induced Edema in Mice (AACR 2024)


Rakuten Medical, Inc. recently presented a poster at the 115th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California, highlighting their groundbreaking study on managing edema following photoimmunotherapy. The presentation, which took place on April 8th, 2024, showcased the company’s innovative approach to reducing photoimmunotherapy-induced edema in mice through the inhibition of COX-2.

The study’s findings suggest that COX-2 inhibition could be a promising strategy for mitigating the side effects associated with photoimmunotherapy, a cutting-edge cancer treatment that combines light-sensitive drugs with targeted light exposure. By effectively managing edema, Rakuten Medical aims to improve patient outcomes and enhance the overall efficacy of this novel therapeutic approach.